“Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer”, FE, vol. 19, no. 1, May 2018, doi: 10.7175/fe.v19i1.1354.